Back to News
Market Impact: 0.2
Biodexa Pharmaceuticals Plc - Depositary Receipt Price Target Increased by 700.00% to $73.44
Source: Nasdaq
Analyst EstimatesAnalyst Insights
Biodexa Pharmaceuticals’ average one-year analyst price target was revised to $73.44 per share, up 700.00% from the prior $9.18 estimate dated October 20, 2026. The figures represent aggregate analyst targets; the article provides no share-price reaction or additional context.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Apple reports after the bell. Options traders expect a big move
- Mizuho lowers Lumentum stock price target on Marvell acquisition
- Why is Apple stock falling afterhours today?
- RA Capital Management sells $9.13M in Lenz Therapeutics shares